Taiwan-based startup JelloX Biotech Inc. has announced a collaboration through a know-how agreement with the prestigious Mayo Clinic in the United States. This partnership aims to advance and validate JelloX’s innovative 3D digital imaging and artificial intelligence (AI) analysis technology.
JelloX has previously gained recognition for participating in the fifth cohort of the Mayo Clinic and Arizona State University Alliance for Health Care MedTech Accelerator. This flagship program is designed to assist early-stage medical device and healthcare technology companies by providing a specialized curriculum to expedite their market entry strategies.
JelloX pioneered a groundbreaking 3D pathology imaging technology incorporating AI for spatial analysis. This technology is designed to enhance precision in cancer diagnosis. Traditional 2D imaging methods often fall short by failing to capture the spatial relationships of critical tumor biomarkers, which can lead to interpretive variability. In contrast, JelloX’s 3D imaging technology offers a more comprehensive view of tissue architecture, providing an enhanced spatial context that promises to improve diagnostic accuracy and consistency. This advancement allows pathologists to deliver more detailed and accurate diagnoses for cancer patients.
In addition to the enhanced imaging capabilities, the same biopsy tissue can undergo further analysis through genomic sequencing and proteomics. This integrated approach aims to offer patients a complete spectrum of precision medicine, tailored to their unique genetic and proteomic profiles.
Dr. Yen-Yin Lin, CEO and founder of JelloX, emphasized the company’s commitment to innovation, stating, “Our goal is to equip researchers and clinicians with more precise diagnostic tools. We also aim to support pharmaceutical companies in developing new drugs, ensuring that patients receive the right treatment at the right time.”
